• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Syros Pharmaceuticals (NQ: SYRS )

    2.450 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Syros Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
    Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
    Via Benzinga
    Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
    Via Benzinga
    TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
    Via Benzinga
    Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate
    The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer. 
    Via Benzinga
    Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
    From Syros Pharmaceuticals, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
    Via InvestorPlace
    Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
    Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
    Via Benzinga
    Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
    Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average... 
    Via Benzinga
    Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    What 4 Analyst Ratings Have To Say About Syros Pharmaceuticals
      Analysts have provided the following ratings for Syros Pharmaceuticals (NASDAQ:SYRS) within the last quarter: 
    Via Benzinga
    Coinbase To $115? Plus This Analyst Cuts PT On Syros Pharmaceuticals By 67%
    Deutsche Bank boosted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $418 to $463. However, Deutsche Bank analyst Faiza Alwy maintained the stock with a Hold rating. FactSet... 
    Via Benzinga
    Citigroup Slashes Price Target On This Stock By 83%; Also Check Out Some Other Big PT Changes
    RBC Capital cut the price target for Nuvei Corporation (NASDAQ: NVEI) from $80 to $60. Nuvei shares fell 21.5% to close at $33.03 on Tuesday. 
    Via Benzinga
    Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Earnings Scheduled For August 9, 2022
    Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
    Via Benzinga
    Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
    Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
    Via Benzinga
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
    Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
    Via Benzinga
    Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
    Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers 
    Via Benzinga
    Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
    From Syros Pharmaceuticals
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
    Via Benzinga
    The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.